Security key
74365U107
Protara Therapeutics, Inc. - Common Stock (TARA)
CUSIP: 74365U107
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 54,239,698
- Total 13F shares
- 5,927,042
- Share change
- -567,926
- Total reported value
- $18,391,293
- Price per share
- $2.93
- Number of holders
- 31
- Value change
- -$2,063,463
- Number of buys
- 9
- Number of sells
- 18
Report period
Q2 2022
Institutions
31
Top holders
10
TARA full security history
Newer quarter: Q3 2022
Previous quarter: Q1 2022
Protara Therapeutics, Inc. SEC filings
Protara Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74365U107
Recent filing periods:
Top shareholders of TARA - Protara Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. |
13F
|
Company |
4.9%
|
2,674,031
|
$13,664,000 | — | 31 Mar 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.5%
|
830,641
|
$4,245,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.79%
|
427,404
|
$2,184,000 | — | 31 Mar 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.75%
|
406,178
|
$2,076,000 | — | 31 Mar 2022 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.71%
|
383,526
|
$1,960,000 | — | 31 Mar 2022 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.55%
|
296,426
|
$1,515,000 | — | 31 Mar 2022 | |
| DLD Asset Management, LP |
13F
|
Company |
0.42%
|
229,531
|
$1,173,000 | — | 31 Mar 2022 | |
| Boxer Capital, LLC |
13F
|
Company |
0.39%
|
209,227
|
$1,069,000 | — | 31 Mar 2022 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.37%
|
199,671
|
$1,020,000 | — | 31 Mar 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.28%
|
152,847
|
$781,000 | — | 31 Mar 2022 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.16%
|
88,779
|
$454,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.15%
|
81,964
|
$418,000 | — | 31 Mar 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.13%
|
72,350
|
$370,000 | — | 31 Mar 2022 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.12%
|
65,918
|
$337,000 | — | 31 Mar 2022 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
64,000
|
$327,000 | — | 31 Mar 2022 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.08%
|
43,741
|
$224,000 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.07%
|
38,916
|
$200,000 | — | 31 Mar 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.07%
|
37,600
|
$192,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.06%
|
30,900
|
$158,000 | — | 31 Mar 2022 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.06%
|
30,606
|
$156,000 | — | 31 Mar 2022 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
27,591
|
$141,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.04%
|
20,019
|
$102,000 | — | 31 Mar 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.03%
|
17,907
|
$92,000 | — | 31 Mar 2022 | |
| Trexquant Investment LP |
13F
|
Company |
0.03%
|
16,313
|
$83,000 | — | 31 Mar 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.03%
|
13,739
|
$70,000 | — | 31 Mar 2022 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.02%
|
12,872
|
$66,000 | — | 31 Mar 2022 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.02%
|
11,730
|
$59,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
6,476
|
$33,000 | — | 31 Mar 2022 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
2,510
|
$13,000 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
745
|
$3,000 | — | 31 Mar 2022 | |
| UBS Group AG |
13F
|
Company |
0%
|
574
|
$3,000 | — | 31 Mar 2022 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
500
|
$3,000 | — | 31 Mar 2022 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0%
|
426
|
$2,000 | — | 31 Mar 2022 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
100
|
$1,000 | — | 31 Mar 2022 | |
| American Portfolios Advisors |
13F
|
Company |
0%
|
100
|
$511 | — | 31 Mar 2022 | |
| Martin Sebastian Olivo |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
14,344
|
$27,397 | — | 10 Jun 2021 |
Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q2 2022
As of 30 Jun 2022,
Protara Therapeutics, Inc. - Common Stock (TARA) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,927,042 shares.
The largest 10 holders included
Opaleye Management Inc., ORBIMED ADVISORS LLC, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, Ikarian Capital, LLC, CITADEL ADVISORS LLC, BOXER CAPITAL, LLC, BAKER BROS. ADVISORS LP, DLD Asset Management, LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
31
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
34
Q2 2022 holders
31
Holder diff
-3
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.